Writing this post made me itchy, read with caution.
Itches are a curious and strange phenomenon. While
conducting observational research on zoo animals, I noticed many of them displaying
similar scratching behaviors to what humans have when we feel a sudden, random
itch. After thinking for a while, I wondered if perhaps non-pathologic itches
maintained some physiological or evolutionary purpose, and thought maybe idiopathic,
non-pathologic itches are one way that our nervous systems might perform “maintenance”
on our nerve function and our bodies, or bring our attention to parts of our
body. But beyond this little idea is the real issue of pathologic itching, or pruritus,
in clinical settings.
Pathologic itching is currently a major clinical challenge
that severely decreases the quality of life for around 1/5th of patients
suffering from various systemic disorders, including ESRD, chronic liver
disease, atopic dermatitis, MS, and neuropathy (Garibyan, Rheingold, & Lerner,
2013) (Callahan and Lio, 2012). This is an issue because the presence of
co-morbid pruritus is linked to an increase in mortality rates compared to
non-itching populations with these disorders (Garibyan, Rheingold, & Lerner,
2013). According to a paper by Callahan and Lio, pathologic itching can be
classified as either acute or chronic. Currently, antihistamine treatments are
effective in treating acute itching, working to counteract histamine-mediated
responses transmitted by C-fibers in the skin. The real issue lies in chronic itching, which anti-histamines
(and practically all other treatments) are ineffective in treating long term.
There is very little understanding of the physiological mechanisms of chronic pruritus,
but a recent study may shine a light in the right direction. Researchers
Kanehisa et Al. found that when a population of mice was low in BHLBH5
transcription factor, they displayed increased chronic itch-behavior
phenotypes. This suggests that chronic itch may result from a loss of SDH (neuronal
circuit) inhibitory interneurons caused by this deficiency. In this study,
these mice populations received transplants of embryonic γ-aminobutyric
acid (GABA)-ergic precursor neurons that expressed hM3Dq receptors into their
SDH. Using DREADD designer drug technology, the researchers used CNO, or clozapine-N-oxide,
to activate the hM3Dq receptors in the neuronal cells, enabling a release of
GABA that suppressed the itching behaviors in the mice. These is still much unknown about how chronic pruritus works, but this research is a strong step in understanding how pathologic itching works and may lead to potential treatments. Further research is needed
before any treatments can be brought into clinical settings.
Cited Sources:
Callahan, S. W., & Lio, P. A. (2012). Current Therapies
and Approaches to the Treatment of Chronic Itch. Current Medical Literature:
Dermatology, 17(2), 29–40. Retrieved from
http://dml.regis.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=77950126&site=ehost-live&scope=site
Garibyan, L., Rheingold, C. G., & Lerner, E. A. (2013). Understanding the pathophysiology of itch. Dermatologic therapy, 26(2), 84-91.
Kanehisa, K., Shiratori-Hayashi, M., Koga, K., Tozaki-Saitoh, H., Kohro,
Y., Takamori, K., & Tsuda, M. (2017). Specific activation of inhibitory
interneurons in the spinal dorsal horn suppresses repetitive scratching in
mouse models of chronic itch. Journal of Dermatological
Science, 88(2), 251-254. doi:10.1016/j.jdermsci.2017.05.017